Skip to main content

Table 2 Clinicopathologic characteristics of patients

From: Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?

Variable

Total, N

No complication group, N (%)

Complication group, N (%)

p

Number of Patients

1081

1022 (94.5)

59 (5.5)

 

Location

   

0.032

 Right

514

484 (94.2)

30 (5.8)

 

 Left

499

478 (95.8)

21 (4.2)

 

 Bilateral

68

60 (88.2)

8 (11.8)

 

Histopathology

   

0.939

 Invasive cancer

841

794 (94.4)

47 (5.6)

 

 DCIS

199

189 (95.0)

10 (5.0)

 

 Other

41

39 (95.1)

2 (4.9)

 

Nuclear grade

   

0.966

 Low

153

144 (94.1)

9 (5.9)

 

 Intermediate

663

627 (94.6)

36 (5.4)

 

 High

265

251 (94.7)

14 (5.3)

 

LVI

   

0.001

 Yes

285

258 (90.5)

27 (9.5)

 

 No

796

764 (96.0)

32 (4.0)

 

Pathologic T

   

0.118

 Tis & pCR

212

207 (97.6)

5 (2.4)

 

 T1

514

484 (94.2)

30 (5.8)

 

 T2

299

280 (93.6)

19 (6.4)

 

 ≥ T3

56

51 (91.1)

5 (8.9)

 

Pathologic N

   

< 0.001

 N0

795

768 (96.6)

27 (3.4)

 

 N1

227

208 (91.6)

19 (8.4)

 

 N2

42

33 (78.6)

9 (21.4)

 

 N3

17

13 (76.5)

4 (23.5)

 

Pathologic prognostic stage

   

0.017

 0 & NRT

207

199 (96.1)

8 (3.9)

 

 I

456

431 (94.5)

25 (5.5)

 

 II

342

326 (95.3)

16 (4.7)

 

 III

76

66 (86.8)

10 (13.2)

 

ER

   

0.445

 Positive

895

844 (94.3)

51 (5.7)

 

 Negative

186

178 (95.7)

8 (4.3)

 

PR

   

0.192

 Positive

842

792 (94.1)

50 (5.9)

 

 Negative

239

230 (96.2)

9 (3.8)

 

C-erbB-2

   

0.586

 Positive

296

280 (94.6)

16 (5.4)

 

 Negative

664

630 (94.9)

34 (5.1)

 

 Unknown

121

112 (92.6)

9 (7.4)

 

Subtype

   

0.880

 HR (+)

900

849 (94.3)

51 (5.7)

 

 HR(−) C-erbB-2(+)

121

116 (95.9)

5 (4.1)

 

 HR(−) C-erbB-2(−)

56

53 (94.6)

3 (5.4)

 

 Unknown

4

4 (100.0)

0 (0.0)

 
  1. DCIS Ductal carcinoma in situ, LVI Lymphovasvular invasion, pCR Pathologic complete response, NRT No residual tumor, HR Hormonal receptor